BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Evaluating the Efficacy Vardenafil 10 mg vs Tadalafil 10 mg in in Subjects With Erectile Dysfunction (ED)
Phase 4
Completed
- Conditions
- Erectile Dysfunction
- Interventions
- First Posted Date
- 2008-04-22
- Last Posted Date
- 2013-10-11
- Lead Sponsor
- Bayer
- Target Recruit Count
- 759
- Registration Number
- NCT00663130
Assessing Efficacy and Safety of Flexible Dosing With Vardenafil in Subjects With Erectile Dysfunction and Hyperlipidemia
Phase 4
Completed
- Conditions
- Erectile Dysfunction
- Interventions
- Drug: Placebo
- First Posted Date
- 2008-04-22
- Last Posted Date
- 2013-10-11
- Lead Sponsor
- Bayer
- Target Recruit Count
- 395
- Registration Number
- NCT00663845
Sorafenib Gastric Cancer Asian Phase I Study
- First Posted Date
- 2008-04-22
- Last Posted Date
- 2013-06-11
- Lead Sponsor
- Bayer
- Target Recruit Count
- 13
- Registration Number
- NCT00663741
Assessment of Duration of Erection With Vardenafil 10 mg
Phase 4
Completed
- Conditions
- Erectile Dysfunction
- Interventions
- Drug: Placebo
- First Posted Date
- 2008-04-22
- Last Posted Date
- 2014-12-30
- Lead Sponsor
- Bayer
- Target Recruit Count
- 201
- Registration Number
- NCT00663728
Levitra® - Real Life Safety and Efficacy of Levitra
- First Posted Date
- 2008-04-22
- Last Posted Date
- 2014-12-19
- Lead Sponsor
- Bayer
- Target Recruit Count
- 30825
- Registration Number
- NCT00663598
Evaluating of the Efficacy and Safety of Vardenafil in Subjects With Erectile Dysfunction
- First Posted Date
- 2008-04-21
- Last Posted Date
- 2009-06-22
- Lead Sponsor
- Bayer
- Target Recruit Count
- 102
- Registration Number
- NCT00662441
Open Label Phase II Study of BAY 43-9006 in Chronic Myelogenous Leukemia (CML) Patients Resistant to Gleevec
Phase 2
Completed
- Conditions
- Chronic Myelogenous Leukemia
- Interventions
- First Posted Date
- 2008-04-18
- Last Posted Date
- 2014-12-23
- Lead Sponsor
- Bayer
- Target Recruit Count
- 10
- Registration Number
- NCT00661180
Depression Related Improvement With Vardenafil for Erectile Response
Phase 3
Completed
- Conditions
- DepressionErectile Dysfunction
- Interventions
- Drug: Placebo
- First Posted Date
- 2008-04-18
- Last Posted Date
- 2014-12-23
- Lead Sponsor
- Bayer
- Target Recruit Count
- 280
- Registration Number
- NCT00661219
Assessment of Efficacy of Vardenafil, Influence on Self-esteem and Self-confidence in Subjects With Erectile Dysfunction
Phase 3
Completed
- Conditions
- Erectile Dysfunction
- Interventions
- Drug: Placebo
- First Posted Date
- 2008-04-18
- Last Posted Date
- 2014-12-30
- Lead Sponsor
- Bayer
- Target Recruit Count
- 129
- Registration Number
- NCT00661596
BAY43-9006 Phase II Study for Renal Cell Carcinoma
- First Posted Date
- 2008-04-18
- Last Posted Date
- 2014-12-25
- Lead Sponsor
- Bayer
- Target Recruit Count
- 131
- Registration Number
- NCT00661375